Meeting Overview - The shareholders' meeting was held on August 1, 2025, at 18 Yingbin Avenue, Leshan High-tech Zone, Sichuan Province [1] - All 9 current directors attended the meeting, along with the board secretary and some senior executives [1] Resolutions Passed - The following proposals were approved during the meeting: - Proposal on the company's compliance for issuing shares to specific targets [2] - Proposal for the 2025 stock issuance plan [3] - Proposal on the types and par value of the shares to be issued [3] - Proposal on the issuance method and timing [3] - Proposal on the issuance targets and subscription methods [3] - Proposal on the pricing benchmark date, pricing principles, and issue price [3] - Proposal on the number of shares to be issued [3] - Proposal on the lock-up period [3] - Proposal on the scale and use of raised funds [3] - Proposal on the arrangement of undistributed profits before this issuance [3] - Proposal on the listing location [3] - Proposal on the validity period of the resolutions [4] - Proposal on the feasibility analysis report for the use of raised funds [4] - Proposal on the shareholder return plan for the next three years (2025-2027) [4] - Proposal on the dilution of immediate returns and measures to compensate [4] - Proposal on signing conditional share subscription agreements with specific targets [4] - Proposal to authorize the board of directors to handle matters related to the issuance of shares [5] - Proposal to approve the exemption of subscription targets from making a takeover offer [5] - Proposal on the special report of previous fundraising usage [5] - Proposal to revise the fundraising usage management system [5] Legal Verification - The meeting was witnessed by Beijing Zhonglun (Chengdu) Law Firm, confirming that the meeting's procedures and resolutions complied with relevant laws and regulations [6]

Core Viewpoint - The company, Shangwei Co., announced the approval of multiple proposals at its second extraordinary general meeting of shareholders in 2025, including the proposal regarding compliance with conditions for issuing shares to specific targets [2] Group 1 - The extraordinary general meeting was held on August 1, where several key proposals were reviewed and approved [2] - One of the main proposals approved was related to the company's eligibility for issuing shares to specific investors [2]

法律意见书 北京中伦（成都）律师事务所 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）等法律、法规及规范性文件及《尚纬股份有限公司章程》（以下 简称"《公司章程》"）的规定，北京中伦（成都）律师事务所（以下简称"中伦" 或"本所"）接受尚纬股份有限公司（以下简称"公司"）的委托，指派本所律 师见证了公司 2025 年第二次临时股东会（以下简称"本次股东会"）并对本次 股东会的相关事项出具本法律意见书。 为出具本法律意见书，中伦律师审查了以下文件： 1. 《公司章程》； 2. 公司第六届董事会第二次会议决议； 3. 《关于召开 2025 年第二次临时股东会的通知》； 4. 公司本次股东会会议文件及现场参会股东资料。 在本法律意见书中，中伦律师仅对本次股东会的召集、召开程序、出席会议 人员资格、召集人资格及会议表决程序、表决结果是否符合《公司法》等法律、 法规、规范性文件及《公司章程》的规定发表意见，不对会议审议的议案内容以 及该等议案所表述的事实或数据的真实性及准确性发表意见。中伦律师无法对网 ...

2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603333 证券简称：尚纬股份 公告编号：2025-056 尚纬股份有限公司 (一)股东会召开的时间：2025 年 08 月 01 日 (二)股东会召开的地点：四川省乐山高新区迎宾大道 18 号 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 500 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 251,050,578 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 40.3925 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次会议由公司董事会召集，公司董事长叶洪林主持。本次会议的召开符合《中 华人民共和国公司法》、《上市公司股东会规则》和《公司章程》的有关规定，会 议合法有效。 (五)公司董事和董事会秘书的出席情况 1、公司在任 ...

Core Viewpoint - The construction of the first commercial controlled nuclear fusion power plant in the U.S. by Helion Energy marks a significant step towards the commercialization of fusion energy, with plans to supply power to Microsoft by 2028 [3][5]. Group 1: Company Developments - Helion Energy has initiated site construction for its controlled nuclear fusion power plant named "Orion" in Chelan County, Washington, which is a crucial milestone for integrating fusion power into the grid [3]. - The company has signed a power purchase agreement with Microsoft to supply 50 MW annually starting in 2028 [5]. - Helion's technology utilizes a magnetic inertial confinement approach, specifically the Field-Reversed Configuration (FRC) method, which is simpler and more cost-effective compared to the Tokamak technology, with construction costs estimated to be only 1/5 to 1/10 of Tokamak systems [5]. Group 2: Industry Context - Other companies in China, such as Hanhai Fusion and Xingneng Xuanguang, are also pursuing similar FRC technology, indicating a growing interest in fusion energy [6]. - A recent industry seminar in Shanghai attracted over 20 companies and nearly 30 financial institutions to discuss the future of controlled nuclear fusion, highlighting its status as a hot topic in the capital market [7]. - Nearly 50 controlled nuclear fusion concept stocks have been actively researched by investors this year, with significant interest in companies like Ice Wheel Environment and Antai Technology, which have received multiple investor inquiries [7]. Group 3: Financial Performance - Several controlled nuclear fusion concept stocks have reported significant earnings growth for the first half of 2025, with Yongding Co. expecting a net profit increase of 731% to 922% year-on-year, primarily due to increased investment income [8]. - Baosheng Co. anticipates a net profit increase of 167.98% to 301.98% for the same period, driven by the market recognition of high-value products [8].

Core Viewpoint - The acquisition involves Fuhua Tongda Chemical Co., Ltd. purchasing shares of Shangwei Co., Ltd. through a private placement, which will increase Fuhua's stake to over 30%, triggering a mandatory tender offer obligation, unless exempted by the shareholders' approval [3][17]. Group 1: Acquisition Details - Fuhua Tongda plans to subscribe for up to 181,338,685 shares at a price of 6.31 RMB per share, with a total subscription amount not exceeding 1,144,247,102.35 RMB [11][16]. - Following the acquisition, Fuhua Tongda's shareholding will increase from 25.35% to 42.21%, maintaining its status as the controlling shareholder of Shangwei [18][10]. - The acquisition is subject to approval from the shareholders' meeting and regulatory bodies, including the Shanghai Stock Exchange and the China Securities Regulatory Commission [3][19]. Group 2: Financial and Operational Background - Fuhua Tongda reported total assets of 1,344,052.07 million RMB and net assets of 372,473.69 million RMB as of December 31, 2024 [8]. - The company has a diversified business model, focusing on mineral resource development and chemical product applications, with key products including glyphosate and its formulations [8][19]. - Fuhua Tongda has not faced any administrative or criminal penalties in the last five years, indicating a stable compliance record [8]. Group 3: Future Plans and Governance - The acquisition aims to enhance Fuhua's control and decision-making capabilities over Shangwei, ensuring long-term strategic stability [9][19]. - There are no immediate plans to change the current board or senior management of Shangwei, but future adjustments may occur based on operational needs [19][20]. - The company intends to modify the articles of association related to registered capital and share capital following the completion of the private placement [19].

Group 1 - The acquisition report by Huatai United Securities for Shangwei Co., Ltd. indicates that the acquisition is based on the recognition of the long-term investment value and development prospects of the listed company [6][9] - The financial advisor confirms that the acquisition report complies with relevant laws and regulations, and no false records or misleading statements were found [16][27] - The acquirer, Fuhua Chemical, has a registered capital of 82,705 million RMB and operates in the chemical industry, focusing on pesticide production and chemical sales [7][9] Group 2 - Fuhua Chemical's financial data shows total assets of 1,344,052.07 million RMB and net assets of 372,473.69 million RMB as of December 31, 2024, with a debt-to-asset ratio of 69.32% [9] - The company reported operating income of 767,189.24 million RMB and a net profit of 60,271.22 million RMB for the year 2024 [9] - The acquirer has committed to maintaining the independence of the listed company and avoiding any conflicts of interest or related party transactions that could harm the company's interests [19][21][23] Group 3 - The acquisition does not involve changes in the actual controller of the listed company, ensuring that the company's operational independence remains intact [19][26] - Fuhua Chemical has outlined plans for potential asset restructuring and business adjustments within the next 12 months, while ensuring compliance with legal requirements [16][18] - The financial advisor has verified that the acquisition funding will come from the acquirer's own or legally raised funds, ensuring the legality of the funding sources [13][14]

Group 1 - The core opinion of the article is that Fuhua Chemical intends to acquire shares of Shangwei Co., Ltd. through a cash subscription, aiming to enhance control and decision-making capabilities over the company [1][9][10] - Fuhua Chemical's basic information includes a registered capital of 82.705 million yuan and a business scope that encompasses pesticide production, chemical products sales, and technology services [2][3] - The shareholding structure indicates that Fuhua Group controls 56.32% of Fuhua Chemical, making it the controlling shareholder [3][4] Group 2 - The acquisition aims to recognize the long-term investment value of Shangwei Co., Ltd. and maintain strategic stability [9][10] - The acquisition process has been approved by the boards of both Fuhua Chemical and Shangwei Co., Ltd., with necessary legal procedures underway [10][12] - The subscription agreement stipulates a maximum of 181,338,685 shares to be acquired at a price of 6.31 yuan per share, which will increase Fuhua Chemical's stake to 42.21% post-acquisition [10][11][13] Group 3 - Fuhua Chemical has committed to not transferring the newly acquired shares for 36 months following the issuance [10][11] - The funding for the acquisition will come entirely from Fuhua Chemical's own funds or legally raised funds, ensuring compliance with relevant regulations [16] - There are no existing legal restrictions on the shares held by Fuhua Chemical, and the company has not faced any significant legal penalties in the past five years [6][14][15]

北京天驰君泰（成都）律师事务所 关于 福华通达化学股份公司免于发出要约事宜 之 法律意见书 法律意见书 北京天驰君泰（成都）律师事务所 法律意见书 北京天驰君泰（成都）律师事务所 关于福华通达化学股份公司免于发出要约事宜之 致：福华通达化学股份公司 根据福华通达化学股份公司（以下简称"福华化学"或"收购人"）的委托， 北京天驰君泰（成都）律师事务所（以下简称"本所"）现就福华通达化学股份 公司免于发出要约事宜，依据《中华人民共和国证券法》《中华人民共和国公司 法》 《上市公司收购管理办法》 《律师事务所从事证券法律业务管理办法》和《律 师事务所证券法律业务执业规则（试行）》等有关法律、行政法规、部门规章的 相关规定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神出具本法律 意见书。 为出具本法律意见书，本所及本所律师特作如下声明： 出具本法律意见书之目的，不包括中国香港特别行政区、中国澳门特别行政区及 中国台湾地区）现行有效的法律、法规及其他规范性文件的规定发表法律意见， 并仅根据对相关事实的了解和对法律的理解发表法律意见。 提供了本所为出具本法律意见书所要求收购人提供的原始书面材料、副本材料、 复印材料 ...

尚纬股份有限公司 收购报告书 | 上市公司： | 尚纬股份有限公司 | | --- | --- | | 上市地点： | 上海证券交易所 | | 股票简称： | 尚纬股份 | | 股票代码： | 603333.SH | | 收购人： | 福华通达化学股份公司 | | --- | --- | | 住所/通讯地址： | 四川省乐山市五通桥区金粟镇 | 签署日期：二〇二五年七月 尚纬股份有限公司 收购报告书 声 明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、本报告书系收购人依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准 则第 16 号——上市公司收购报告书》及相关的法律、法规编写本报告书。 二、依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司 收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 16 号——上 市公司收购报告书》的规定，本报告书已全面披露收购人在尚纬股份拥有权益的 股份。 三、截至本报告书签署日，除本报告书披露的持股信息外，收购人没有通过 任何其他方式在尚纬股份拥有权益。 四、收 ...